ZyVersa Therapeutics, Inc.

ZyVersa Therapeutics (ZVSA) showed no cyber incidents or red-flag 8-K filings in our 90-day monitoring window, suggesting operational stability in the near term. However, a compressed lookback period captures limited signal; the full Report extends analysis to 12 months of filing activity, tracks dilution risk from equity issuances, and maps financing history against clinical and cash-burn milestones. We also flag AI-derived risk signals tied to leadership changes, pipeline delays, and regulatory setbacks that may not yet appear in headline filings. The full $49 Report adds dilution scoring, 8-K context and timing analysis, multi-year financing trajectories, and machine-flagged early warning indicators.